Response to Comment on Feig et al. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care 2018;41:2471–2479

We thank Sacha and Lane (1) for their interest in our multicenter, multinational randomized Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT). First, we should clarify that the randomized controlled trial was designed to evaluate the impact of continuous glucose monitoring (CGM) in women with type 1 diabetes (T1D) who were pregnant or planning pregnancy (2). Of note, CGM was beneficial on a range of maternal second and third trimester glycemic outcomes, with a halving in the odds ratio for neonatal large for gestational age, neonatal hypoglycemia, and neonatal intensive care unit admissions >24 h (3). Furthermore, the treatment effect of CGM was comparable across 31 international sites and between women using insulin pumps and contemporary multiple daily injection (MDI) regimens. Given the paucity of randomized trial data comparing insulin pumps with MDI using contemporary fast- and long-acting …